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Characterization of Innate Lymphoid Cells in
Human Skin and Blood Demonstrates Increase
of NKp44þ ILC3 in Psoriasis
Federica Villanova1,2,5, Barry Flutter1,5, Isabella Tosi1,2, Katarzyna Grys1,2, Hemawtee Sreeneebus1,2,
Gayathri K. Perera1,3, Anna Chapman4, Catherine H. Smith1, Paola Di Meglio1,6 and Frank O. Nestle1,2
Innate lymphoid cells (ILCs) are increasingly appreciated as key regulators of tissue immunity. However, their
role in human tissue homeostasis and disease remains to be fully elucidated. Here we characterize the ILCs in
human skin from healthy individuals and from the inflammatory skin disease psoriasis. We show that a
substantial proportion of IL-17A and IL-22 producing cells in the skin and blood of normal individuals and
psoriasis patients are CD3-negative innate lymphocytes. Deep immunophenotyping of human ILC subsets
showed a statistically significant increase in the frequency of circulating NKp44þ ILC3 in the blood of psoriasis
patients compared with healthy individuals or atopic dermatitis patients. More than 50% of circulating NKp44þ
ILC3 expressed cutaneous lymphocyte–associated antigen, indicating their potential for skin homing. Analysis of
skin tissue revealed a significantly increased frequency of total ILCs in the skin compared with blood. Moreover,
the frequency of NKp44þ ILC3 was significantly increased in non-lesional psoriatic skin compared with normal
skin. A detailed time course of a psoriasis patient treated with anti–tumor necrosis factor showed a close
association between therapeutic response, decrease in inflammatory skin lesions, and decrease of circulating
NKp44þ ILC3. Overall, data from this initial observational study suggest a potential role for NKp44þ ILC3 in
psoriasis pathogenesis.
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INTRODUCTION
The skin is the primary interface with the external environment
and thus it is required to provide the first line of host defense
against injury and infection (Kupper and Fuhlbrigge, 2004; Di
Meglio et al., 2011). Similar to lung and gut mucosal barriers,
the skin is equipped with a diverse set of immune cells that are
poised to react to different insults, yet retain the potential to
cause autoimmunity.
Plaque-type psoriasis is a chronic inflammatory skin disease
characterized by highly inflamed scaly lesions resulting from
hyperproliferation of the epidermis and a prominent inflamma-
tory infiltrate (Griffiths and Barker, 2007; Nestle et al., 2009).
The immunopathogenesis of psoriasis is based on a combination
of genetic susceptibility and environmental risk factors triggering
a pathogenic cross-talk between innate and adaptive immune
cells (Lowes et al., 2013). Recent advances in understanding the
genetic basis of the disease suggest a significant involvement of
the innate immune system. Indeed, 11 out of 36 psoriasis
susceptibility loci identified in individuals of European ancestry
encode plausible regulators of innate host defense (Tsoi et al.,
2012). The IL-23/IL-17/IL-22 axis bridges innate and adaptive
immunity and is of critical importance in psoriasis (Diveu et al.,
2008; Di Cesare et al., 2009). Although a contribution of
conventional ab T cells to IL-17 and IL-22 cytokine produc-
tion is well-established (Hijnen et al., 2013), the contribution of
innate immune cell subsets is less well understood. Recent data
in both mouse experimental models (Pantelyushin et al., 2012)
and in human immune-mediated pathologies, such as Crohn’s
disease (Geremia et al., 2011), have established a potential role
of innate lymphoid cells (ILCs) as key sources of IL-17 and IL-22
production in epithelial inflammatory disease.
ILCs are recombination-activating gene–independent cells
and are identified by their lymphoid morphology as well as
the absence of lineage markers for T/B cells and for other
innate cells (Spits et al., 2013). Three ILC groups have been
described in both mouse and humans, related by their
dependence on the transcriptional repressor inhibitor of
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DNA binding 2 (Id2) and on the IL-2Rg chain (Yokota et al.,
1999). The ILC3 subset, which also includes lymphoid tissue
inducer cells, is dependent on the transcription factor RORgT,
as well as on the expression of the IL-7Ra chain. ILC3 can
produce IL-17A and/or IL-22 upon stimulation (Takatori et al.,
2009). In humans, ILC3 can be subdivided on the basis of the
expression of the natural cytotoxicity receptors NKp44,
NKp46, and NKp30 (Cella et al., 2009). NKp44þ ILC can
produce IL-22 and are dependent on the aryl hydrocarbon
receptor; conversely, human lymphoid tissue inducer cells and
other NKp44 ILC3 produce IL-17A following stimulation
(Hoorweg et al., 2012). However, NKp44þ ILC3 isolated
from the tonsil produce both IL-17 and IL-22, whereas
NKp44 ILC3 show considerable plasticity, being able to
develop either into NKp44þ ILC3 or into ILC1 cells
producing IFNg (Bernink et al., 2013). ILC3 have been
shown to produce IL-17 in the gut of inflammatory bowel
disease patients (Bernink et al., 2013), suggesting a potential
role in immune-mediated diseases such as colitis and psoriasis.
Despite the growing interest about innate sources of
proinflammatory cytokines, the ILC populations of human
skin are ill-defined. Here, we explore their presence in
psoriasis, as well as in the healthy skin and another inflam-
matory skin disease, atopic dermatitis (AD). We demonstrate
that CD3-negative (CD3 ) innate lymphocytes are major
contributors to IL-17 and IL-22 production in both blood and
skin of healthy individuals and psoriasis patients. We further
show that the NKp44þ ILC3 subset of ILCs, previously
demonstrated to produce IL-17 and IL-22 (Bernink et al.,
2013), is increased in frequency in both the peripheral blood
and skin of psoriasis patients. Interestingly, in a psoriasis
patient with a high baseline frequency of NKp44þ ILC3, the
clinical response to anti–tumor necrosis factor (TNF) therapy
was associated with a decrease of this population in the
blood, implying that it may be either a useful biomarker or
even a contributor to disease.
RESULTS AND DISCUSSION
Identification of a population of IL-17 and IL-22 producing
CD3 immune cells in the blood and skin of psoriatic patients
We recently embarked on a systematic analysis of peripheral
immune cells in patients with inflammatory skin disease.
During our analysis of Th17 cells in the blood of psoriasis
patients, we observed that there was a consistent population of
CD3 innate lymphocytes capable of producing IL-17A. Simi-
larly, when we assessed IL-22 production, we could readily
identify CD3 cells, which were making IL-22 (Figure 1a and
b). In the peripheral blood, these cells account for about 20%
of IL-17 (normal, mean: 15.65%±1.95; psoriasis, mean:
21.83±4.40%) and about 40% of IL-22 (normal, mean:
41.49%±4.04; psoriasis, mean: 39.95%±4.91) producing
cells. To assess whether these cytokine-producing CD3 cells
are also present in the skin, we isolated cells from the skin of
normal healthy individuals (N) or patients with either psoriasis
(P) or AD (A). Distinct populations of CD3þ and CD3 cells
could be clearly identified in the skin and CD3 discrimination
was not affected by enzymatic tissue digestion; fluorescence
minus one control and isotype controls were used to define the
CD3 gate and exclude nonspecific binding (Supplementary
Figure S1 online). In agreement with our peripheral blood data,
CD3 IL17þ cells could be clearly identified in the dermis
and epidermis of healthy normal skin (NN), lesional (PP), and
non-lesional (PN) skin of psoriatic, as well as in lesional (AA)
and non-lesional (AN) skin of AD patients (Figure 1c and
Supplementary Figure S2 online). CD3 IL-22þ cells could
be identified in epidermal samples from healthy volunteers,
psoriasis and AD patients; they could not be identified in
normal dermis (NN), but could be found in both non-lesional
(PN and AN) and lesional samples (PP and AA) from patients
with skin disease (Figure 1 and Supplementary Figure S2
online). The frequency of these cells varied considerably
between individuals (Supplementary Figure S2 online) and as
a result no statistically significant differences were observed;
however, non-lesional psoriatic epidermis seemed to harbor
the highest median frequency of CD3 IL-17þ and CD3
IL-22þ cells (15.9% and 3.8% of CD45þ cells, respectively).
In addition, we performed dermal explant cultures of NN
(n¼2), PP (n¼5), and PN (n¼2) skin, allowing cells to
migrate out of the tissue over 4–5 days. Migratory immune
cells confirmed the presence of CD3 cells capable of
producing IL-17 (Figure1d), as well as IL-22 (data not shown).
Our data point to the existence of an IL-17 and IL-22
producing CD3 immune cell subset in the blood and skin of
healthy individuals and patients with inflammatory skin disease.
Extensive immunophenotyping of psoriasis peripheral blood cells
reveals an enrichment in NKp44þ ILC3
To further dissect immune cells subsets in healthy individuals
and patients with psoriasis or AD, we performed extensive
immunophenotyping of peripheral blood mononuclear cells
(PBMCs). No apparent differences were found in the popula-
tions of T, B, natural killer, and myeloid cells between healthy
individuals and patients with inflammatory skin disease
(Figure 2a). On the basis of the recent demonstration of ILCs
as important contributors to IL-17 and IL-22 production in
models of inflammatory skin disease (Pantelyushin et al.,
2012) and gut inflammation (Geremia et al., 2011), we
developed a panel of antibodies (Supplementary Table 4
Figure 1. Identification of CD3-negative (CD3 ) lymphocytes in blood and skin that produce IL-17 and IL-22. Peripheral blood mononuclear cells
(PBMCs) or skin cells from psoriasis patients (P), healthy individuals (N), or atopic dermatitis (AD) patients were stimulated with phorbol 12-myristate
13-acetate/ionomycin and stained for surface markers and cytokines for flow cytometric analysis. (a) Representative plots showing IL-17A and IL-22 production in
PBMCs from N (n¼ 16) and P (n¼16). (b) Frequencies of CD3 cells within IL-17Aþ or IL-22þ cells in PBMCs. (c) Representative dot plots for CD3 cells
producing IL-17 and IL-22 from the epidermis and dermis of normal (NN, n¼ 4 (epidermis), 5 (dermis)), psoriasis non-lesional (PN, n¼ 4 (epidermis),
3 (dermis)), psoriasis lesional (PP, n¼5 (epidermis and dermis)), AD non-lesional (AN, n¼ 5 (epidermis), 2 (dermis)), and AD lesional (AA, n¼8 (epidermis),
7 (dermis)) skin. (d) Representative plots of dermal skin explants from NN (n¼2), PN (n¼ 2), and PP (n¼5) skin.
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online) allowing for the differentiation between the major
human ILC subsets (Spits et al., 2013). Analysis of the total ILC
population defined as lymphoid/CD45þ /Lin /CD127þ in
PBMCs of healthy individuals showed a mean frequency of
0.06±0.01% (n¼9) in agreement with previously reported
data (Bernink et al., 2013). The total ILC frequency was similar
in psoriasis patients (n¼11, mean 0.05±0.01%) compared
with healthy controls, but was somewhat decreased in AD
patients (n¼10, mean 0.03±0.01%, Po0.05 vs. normal)
(Figure 2b). The distinct populations of ILCs were defined as
shown in Figure 2b: ILC2 (CRTH2þ , green frame), ILC3
(CRTH2 CD117þ ) and either NKp44 (purple frame) or
NKp44þ (orange frame), and ILC1 (CRTH2 /CD117 /
CD161þ , pink frame). Figure 2c shows the distribution of
the different subsets, as mean frequency, in normal, psoriasis,
and AD patients. In healthy individuals, the NKp44 ILC3
population was the most frequent, accounting for more than
40% of all ILCs (median: 45%, (36–54%)). The frequency of
ILC1 and ILC2 varied somewhat among healthy individuals
(ILC1 median: 24% (19–42%) and ILC2 median: 25% (19–
45%)) (Figure 2c). Noticeably, the NKp44þ population of
ILC3 was negligible in healthy individuals ranging from
undetectable to 1% in eight out of nine individuals and 4%
in one additional individual. No significant differences were
observed in the distribution of ILC subsets in AD patients
compared with healthy volunteers (Figure 2c). However, in
psoriasis patients there was a statistically significant (Po0.05)
increase in the median frequency of NKp44þ ILC3 cells from
0.2% (0–3.9%) in healthy individuals to 2.6% (0.1–53%) in
patients (Figure 2d). The frequency of NKp44þ ILC3 in
psoriasis patients appeared to be bimodally distributed, with
one group of patients having low frequencies similar to those
seen in healthy individuals (6 of 11) and a second group in
which the NKp44þ ILC3 population ranged from 9.2 to 53%
of ILC (5 of 11). Although the relatively small number of
patients makes it difficult to perform proper stratification, no
association was found between the bimodal frequency of
NKp44þ ILC3 and either psoriasis patient clinical or demo-
graphic features (age, sex, psoriasis area severity index (PASI),
age of disease onset, presence of comorbidities), or the
frequency of other peripheral cell populations (cutaneous
lymphocyte–associated antigen-positive (CLAþ ) ILCs, CD3,
CD4 and CD8 T cells, T regulatory cells, T-helper type 17,
natural killer cell, monocytes, and dendritic cell). Further
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Figure 2. Deep immunophenotyping of peripheral blood mononuclear cells (PBMCs) shows increased frequency of NKp44þ innate lymphoid cell 3
(ILC3) in the blood of psoriasis patients. (a) Mean frequencies±SEM of myeloid (top) and lymphocytic (bottom) cell populations within PBMCs of psoriasis (P)
(black, n¼ 9), healthy individuals (N) (white, n¼ 7), and AD patients (A) (gray, n¼10). (b) Analysis of total ILCs defined as LinCD127þ within live
CD45þ lymphocytes in P (n¼ 11), N (n¼9), and A (n¼10) (mean %±SEM). ILC subpopulations were defined as shown in representative plots: ILC1 (pink),
ILC2 (green), NKp44þ ILC3 (orange), and NKp44 ILC3 (purple). (c) Pie charts showing average frequencies of ILC subpopulations in P, N, and A. (d) Median
frequencies of NKp44þ ILC3; each filled (P), empty (N), or shaded triangle (A) represents an individual donor. Kruskal–Wallis, followed by Dunn’s multiple
comparison test was performed, *Po0.05. DC, dendritic cell; Mo, monocyte; NK, natural killer cell; Treg, regulatory T cell.
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studies are required to confirm or rule out a genetic influence
on the cell frequency of this population.
Successful treatment of psoriasis with anti-TNF antibody is
associated with a decrease of circulating NKp44þ ILC3: a
case study
We next asked whether NKp44þ ILC3 frequencies change
during treatment of psoriasis with cytokine-targeted therapy.
TNF synergizes with IL-23 to drive IL-17A production by ILC
(Powell et al., 2012). We had the opportunity to closely follow
the clinical progression of patient P21 who had the highest
frequency of circulatory NKp44þ ILC3 during treatment with
an anti-TNF mAb (adalimumab). P21 was off any systemic
treatment at the time the initial blood sample was taken and
was then commenced on adalimumab. The PASI, which
measures disease severity, was 21.2, indicating substantial
disease. Subsequent blood samples were taken at 1, 4, and 12
weeks after commencing treatment. There were no gross
changes in the frequencies of B cells, natural killer cells,
myeloid cells, or T cells during adalimumab therapy
(Figure 3a). In contrast, there was a marked shift in the
frequencies of ILC3 populations in the blood with a 75%
reduction in the NKp44þ ILC3 population and a correspond-
ing increase in the NKp44 ILC3 population (Figure 3b). The
shift in the absolute number of NKp44þ ILC3 was closely
associated with a reduction in disease severity and extent
measured by PASI, which decreased from 21.2 to 13.6 over
time during treatment with adalimumab (Figure 3c).
Although only a single case, this result is potentially
instructive, suggesting that frequency of circulating NKp44þ
ILC3 might reflect disease severity and/or response to treat-
ment with anti-TNF therapy. In addition, it highlights a
potential role for TNF in the differentiation of human
NKp44þ ILC3, which could be the subject of further
investigation beyond the scope of this initial descriptive study.
ILC3 preferentially express the skin-homing CLA
To assess if there is a population of ILCs with skin-homing
potential, we analyzed the expression of the skin-homing
marker CLA on ILC populations and T cells in the blood.
Interestingly, ILCs of healthy individuals expressed CLA at high
frequency (mean 33±4%), significantly higher than on CD8 T
cells (mean 11±5%, Po0.01) and higher than on CD4 T cells
(mean 18±5%), although this did not reach statistical sig-
nificance (Figure 4a). A significant increase in the frequency of
CLAþ ILCs was also seen in the blood of psoriasis and AD
patients where the frequency of CLA expression was 2- to 4-
fold higher on ILCs than on either CD4 or CD8 T cells
(Figure 4a). In healthy individuals, the expression of CLA on
NKp44 ILC3 was particularly high (mean 48±15%),
and significantly increased when compared with ILC2
(Po0.05; mean 18±12%). Similarly, the expression of CLA
was also high on NKp44 ILC3 in patients with inflammatory
skin disease (psoriasis, mean 56±22%; AD, mean 56±16%)
(Figure 4b).
NKp44þ ILC3 were only present at high enough frequency
in psoriasis patients to assess CLA expression; interes-
tingly, these cells expressed similarly high levels of CLA to
NKp44 ILC3 and significantly more than ILC2 (psoriasis,
mean % CLAþ : NKp44þ ILC3 54±18% vs. ILC2 14±4%,
Po0.001). These results imply that both circulating
NKp44 and NKp44þ ILC3 express skin-homing markers
and are poised to home to the skin.
NKp44þ ILC3 are increased in PN and PP skin of psoriasis
patients
To confirm their role in skin inflammation, we isolated and
characterized ILCs in skin biopsies from psoriasis patients and
skin obtained from healthy individuals after surgical proce-
dures. We did not have the opportunity to investigate the skin
of AD patients, where clearly ILC2 are increased in the
lesional skin (Kim et al., 2013). In preliminary experiments,
we found that optimal cell yield/viability was obtained by
collagenase digestion of whole skin. Gating strategy and
representative plots of the different ILC subsets in healthy
and psoriasis skin are shown in Figure 4c. ILC populations
were significantly enriched in the skin compared with blood
(PP skin vs. P blood, Po0.01; NN skin vs. N blood, Po0.001),
with a median frequency of 0.6% (0.4–4.4%) of CD45þ
lymphocytes in normal skin (n¼ 6) and 1.4% (1.0–2.3%) in
lesional psoriasis skin (n¼ 5) (Figure 4d), which represents
over 10- and 30-fold more, respectively, than the frequencies
observed in blood (Figure 2b).
ILC populations in normal skin (n¼6) were variable
between individuals (ILC1 median: 19% (9–32%); ILC2
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median: 16.3% (4–69%); ILC3 NKp44 median: 46% (9–
65%); ILC3 NKp44þ median: 13% (5–24%)). Figure 4e
shows distribution of the different subsets, as the mean
frequency, in normal, non-lesional, and lesional psoriasis skin.
Interestingly, the overall frequency of ILCs in PN skin was
significantly increased compared with healthy skin (median
2.9% (2.2–5.1%), PN vs. NN, Po0.05) (Figure 4d). Moreover,
the distribution of ILC populations was highly skewed, with a
significant enrichment of the NKp44þ ILC3 to a median
frequency of 48% (34–54%) (PN vs. NN, Po0.05) (Figure 4f).
This population also appeared to be enriched in psoriasis
lesions in comparison with normal skin, although this did not
reach statistical significance (median 31% (13–47%))
(Figure 4f). However, because of the overall enrichment of
ILCs in lesional (PP) compared with PN skin (PP median:
2,100 (500–3,600) ILC per cm2 skin. PN median: 800 (100–
1,400) ILC per cm2 skin), there was an increased overall
density of NKp44þ ILC3 in each lesional (PP) sample when
compared with the matched non-lesional sample (PN) (n¼5,
PP median 440 (250–1,200) cells per cm2 skin, PP median
260 (60–770) cells per cm2 skin, PN vs. PP, Po0.05).
The enrichment of ILCs in the skin suggests that these cells
are important players in tissue immunity. The increase in
frequency of ILCs and particularly the NKp44þ ILC3 subset in
non-inflamed skin of psoriasis patients is particularly interest-
ing, as it indicates that these cells are not bystanders recruited
to the skin following T cell activation. NKp44þ ILC3 have
previously been shown to produce IL-17 and IL-22 (Bernink
et al., 2013), which is consistent with the trend observed of
increased CD3 cytokine-producing cells in PN samples
(Figure 1c and Supplementary Figure S2 online). The enrich-
ment in PN samples suggests that these cells may be
strategically placed and poised to start the psoriatic disease
process if appropriate stimuli occur. As such, they could
represent the innate counterparts to the tissue-resident mem-
ory T cells of adaptive immunity, which are known to reside in
the skin to act as the first line of defense in the tissue (Boyman
et al., 2007; Clark, 2010) and provide long-term peripheral
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immunity (Gebhardt et al., 2009; Jiang et al., 2012). Activation
of resident memory T cells is necessary and sufficient for the
development of psoriatic lesions from human non-lesional
skin transplanted onto an AGR129-immunodeficient mouse
(Boyman et al., 2004), and skin-resident ILCs could contribute
by providing the necessary activation signals. In this sense,
ILCs would have a role in initiating the psoriasis plaque,
which is then sustained by proliferating T cells, which are
present at high frequency in lesional skin. Further studies, for
instance using the xenotransplant model (Boyman et al.,
2004), are required to elucidate ILC function in initiating the
psoriasis plaque.
Our findings are complementary but distinct to our previous
description of the role of Vg9Vd2 gd T cells in psoriasis, which
are recruited to the psoriasis skin under inflammatory condi-
tions (Laggner et al., 2011). Our observation that Vg9Vd2 gd
T cells represent only a minority of IL-17 production in
non-lesional skin is now explained by the discovery of
NKp44þ ILC3 as potentially major innate contributors of
IL-17 and IL-22 production in conditions of skin homeostasis
and inflammatory pathology.
Taken together, we establish a potentially important role for
NKp44þ ILC3 in the pathogenesis of psoriasis paving the way
for the investigation of such cells as therapeutic targets or
biomarkers in the management of psoriasis.
MATERIALS AND METHODS
Subjects
Thirty-six healthy individuals (18 men and 18 women; mean age 44
years) were included in the study. Thirty-four psoriatic (29 men and 5
women; mean age 42 years) and 10 AD (5 men and 5 women; mean
age 37 years) patients were recruited at St John’s Institute of
Dermatology (Guy’s and St Thomas’ Hospital), West Middlesex
University Hospital, and Queen Elizabeth Hospital, after examination
by expert clinicians. Unless otherwise stated in Supplementary Table 2
online, psoriasis and AD patients were off biologic and systemic
immunosuppressive therapy for at least 2 weeks. Full demographics of
participants are provided in Supplementary Tables 1–3 online. Our
study was conducted in accordance with the Declaration of Helsinki
Principles, written informed consent was obtained from each partici-
pant, and approved by the institutional review board of Guy’s and
St Thomas’ Hospital (Guy’s Research Ethics Committee, Reference 06/
Q0704/18) and London Bridge (London Bridge Research Ethics
Committee, Reference 11/LO/1962).
Sample collection
Skin biopsies (4–6 mm punch biopsy) were obtained from psoriasis
and AD patients from both lesional and non-lesional skin, and healthy
discarded skin was obtained from plastic surgery. One psoriatic
patient (P21; Supplementary Table 2 online and Figure 3) was
followed during the course of therapy with adalimumab (human
mAb anti-TNF), with blood collected before and after 1, 4, and 12
weeks of therapy.
PBMC isolation and storage
PBMCs were isolated from the blood by density centrifugation over
Lymphocyte Separation Medium LSM 1077 (PAA Laboratories,
Pasching, Austria) and frozen in RPMI 1640 (Life Technologies,
Carlsbad, CA) containing 11.25% human serum albumin (Gemini
Bio-Products, West Sacramento, CA)þ 10% DMSO (Sigma, St Louis,
MO) and stored in liquid nitrogen.
Skin sample processing
Skin immune cells were obtained either by spontaneous migration out
of the tissue (dermal explants) or by enzymatic isolation.
Dermal explants: Epidermis and dermis were separated using
dispase (5 mg ml 1; StemCell, Grenoble, France) treatment at 4 1C
overnight. The dermis was then cut into small pieces and cultured in
complete RPMI (RPMI containing 1% penicillin/streptomycin and 10%
fetal calf serum; all from Life Technologies) for 3–5 days at 37 1C/5%
CO2. Non-plastic adherent cells that had migrated out of the dermis
3–5 days after culture were harvested for flow cytometric analysis.
Enzymatic isolation: Epidermis and dermis were separated using
EDTA treatment (15 mM; Life Technologies) for 1 hour at 37 1C
and then incubated in collagenase (0.8 mg ml 1; Worthington,
Lakewood, NJ) at 4 1C overnight. For whole skin fresh cell suspen-
sions, the skin was incubated in collagenase overnight at 37 1C.
Multiparameter flow cytometry
PBMCs were thawed and either stimulated for intracellular cytokine
production on a custom-made stimulation lyoplate (BD Biosciences,
San Jose, CA) containing phorbol 12-myristate 13-acetate, ionomycin,
and golgi inhibitors (monensin and brefeldin A), at 37 1C/5% CO2 for
5 hours and stained on a custom-made staining lyoplate (BD Bio-
sciences) as described previously (Villanova et al., 2013) or stained
with liquid antibody cocktails for surface markers.
Skin cells were either stimulated with phorbol 12-myristate
13-acetate (Sigma; 50–100 ng ml 1), ionomycin 1mg ml 1 (Calbio-
chem, Darmstadt, Germany), monensin (BD Bioscience; 3mM), and/or
brefeldin A (BD Bioscience; 5mM) at 37 1C/5% CO2 for 5 hours and
stained with liquid cocktails for intracellular cytokine production, or
stained with liquid antibody cocktail for surface marker analysis.
Lyophilized antibody present on lyoplates and liquid antibodies
used are listed in Supplementary Table 4 online.
Intracellular staining was performed using the BD Human
Foxp3 Buffer kit (BD Bioscience) according to the manufacturer’s
instructions. Dead cells were excluded from the analysis by staining
with Live Dead Aqua/Yellow (Life Technologies).
Samples were acquired on a SORP Fortessa (BD Bioscience), and
data analyzed using the DIVA software (BD Bioscience) or FlowJo
software (Treestar, Ashland, OR).
Statistical analysis
Indicated populations were assessed for normal Gaussian distribution
with D’Agostino and Pearson omnibus normality test and then
analyzed by one-way analysis of variance, followed by Bonferroni
post test or Kruskal–Wallis, followed by Dunn’s multiple comparison
test, as appropriate, using Prism version 5.0 (GraphPad Software,
La Jolla, CA). Paired lesional and non-lesional skin samples were
compared using Wilcoxon’s signed-rank test. Unless stated otherwise,
mean values are given±SEM and median values with (range). Values
of Po0.05 were considered significant.
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